OSBORNE DAVID W 4

4 · Arcutis Biotherapeutics, Inc. · Filed Mar 3, 2020

Form 4

Period: 2020-02-27

Chief Technical Officer

Transactions

Award
Common Stock
2020-02-27+9,000→ 279,279 total
Award
Stock Option (Right to Buy)
2020-02-27+12,000→ 12,000 total
Exercise: $27.61Exp: 2030-02-27→ Common Stock (12,000 underlying)

Holdings

Footnotes (5)

[F1]Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
[F2]Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024.
[F3]The securities are held of record by The Osborne Irrevocable Trust FBO John Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
[F4]The securities are held of record by The Osborne Irrevocable Trust FBO Sharon Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
[F5]The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024.

Documents

1 file